Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia - PubMed (original) (raw)

. 2014 May;28(5):1060-70.

doi: 10.1038/leu.2013.319. Epub 2013 Oct 30.

B Gizdic 2, S Serra 3, T Vaisitti 1, C Ciardullo 4, M Coscia 5, L Laurenti 6, G D'Arena 7, O Jaksic 8, G Inghirami 9, D Rossi 4, G Gaidano 4, S Deaglio 3

Affiliations

• PMID: 24170027
• DOI: 10.1038/leu.2013.319

Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia

F Arruga et al. Leukemia. 2014 May.

Abstract

The purpose of this study was to compare the expression and function of NOTCH1 in chronic lymphocytic leukemia (CLL) patients harboring a wild-type (WT) or mutated NOTCH1 gene. NOTCH1 mRNA and surface protein expression levels were independent of the NOTCH1 gene mutational status, consistent with the requirement for NOTCH1 signaling in this leukemia. However, compared with NOTCH1-WT CLL, mutated cases displayed biochemical and transcriptional evidence of an intense activation of the NOTCH1 pathway. In vivo, expression and activation of NOTCH1 was highest in CLL cells from the lymph nodes as confirmed by immunohistochemistry. In vitro, the NOTCH1 pathway was rapidly downregulated, suggesting that signaling relies upon micro-environmental interactions even in NOTCH1-mutated cases. Accordingly, co-culture of Jagged1(+) (the NOTCH1 ligand) nurse-like cells with autologous CLL cells sustained NOTCH1 activity over time and mediated CLL survival and resistance against pro-apoptotic stimuli, both abrogated when NOTCH1 signaling was pharmacologically switched off. Together, these results show that NOTCH1 mutations have stabilizing effects on the NOTCH1 pathway in CLL. Furthermore, micro-environmental interactions appear critical in activating the NOTCH1 pathway both in WT and mutated patients. Finally, NOTCH1 signals may create conditions that favor drug resistance, thus making NOTCH1 a potential molecular target in CLL.

PubMed Disclaimer

Similar articles

• NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.
  Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, Martorelli D, Bravin V, D'Agaro T, Rossi FM, Bomben R, Santinelli E, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Poeta G, Rossi D, Gaidano G, Dal Bo M, Gattei V, Zucchetto A. Benedetti D, et al. Leukemia. 2018 Mar;32(3):654-662. doi: 10.1038/leu.2017.296. Epub 2017 Sep 22. Leukemia. 2018. PMID: 28935990
• _SF3B1_-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation.
  Pozzo F, Bittolo T, Tissino E, Vit F, Vendramini E, Laurenti L, D'Arena G, Olivieri J, Pozzato G, Zaja F, Chiarenza A, Di Raimondo F, Zucchetto A, Bomben R, Rossi FM, Del Poeta G, Dal Bo M, Gattei V. Pozzo F, et al. Haematologica. 2021 Dec 1;106(12):3125-3135. doi: 10.3324/haematol.2020.261891. Haematologica. 2021. PMID: 33121237 Free PMC article.
• NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.
  Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi FM, Zucchetto A, Tissino E, Degan M, D'Arena G, Di Raimondo F, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M. Pozzo F, et al. Leukemia. 2017 Nov;31(11):2407-2415. doi: 10.1038/leu.2017.90. Epub 2017 Mar 21. Leukemia. 2017. PMID: 28321119
• Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
  Rodríguez-Vicente AE, Díaz MG, Hernández-Rivas JM. Rodríguez-Vicente AE, et al. Cancer Genet. 2013 Mar;206(3):49-62. doi: 10.1016/j.cancergen.2013.01.003. Epub 2013 Mar 24. Cancer Genet. 2013. PMID: 23531595 Review.
• Interactions between bone marrow stromal microenvironment and B-chronic lymphocytic leukemia cells: any role for Notch, Wnt and Hh signaling pathways?
  Seke Etet PF, Vecchio L, Nwabo Kamdje AH. Seke Etet PF, et al. Cell Signal. 2012 Jul;24(7):1433-43. doi: 10.1016/j.cellsig.2012.03.008. Epub 2012 Mar 13. Cell Signal. 2012. PMID: 22446006 Review.

Cited by

• Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape.
  Mangolini M, Maiques-Diaz A, Charalampopoulou S, Gerhard-Hartmann E, Bloehdorn J, Moore A, Giachetti G, Lu J, Roamio Franklin VN, Chilamakuri CSR, Moutsopoulos I, Rosenwald A, Stilgenbauer S, Zenz T, Mohorianu I, D'Santos C, Deaglio S, Hodson DJ, Martin-Subero JI, Ringshausen I. Mangolini M, et al. Nat Commun. 2022 Oct 20;13(1):6220. doi: 10.1038/s41467-022-33739-2. Nat Commun. 2022. PMID: 36266281 Free PMC article.
• Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation.
  Onaindia A, Gómez S, Piris-Villaespesa M, Martínez-Laperche C, Cereceda L, Montes-Moreno S, Batlle A, de Villambrosia SG, Pollán M, Martín-Acosta P, González-Rincón J, Menarguez J, Alvés J, Rodriguez-Pinilla SM, García JF, Mollejo M, Fraga M, García-Marco JA, Piris MA, Sánchez-Beato M. Onaindia A, et al. Haematologica. 2015 May;100(5):e200-3. doi: 10.3324/haematol.2014.117705. Epub 2014 Dec 31. Haematologica. 2015. PMID: 25552700 Free PMC article. No abstract available.
• Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation.
  De Falco F, Sabatini R, Falzetti F, Di Ianni M, Sportoletti P, Baldoni S, Del Papa B, Screpanti I, Marconi P, Rosati E. De Falco F, et al. Leukemia. 2015 Apr;29(4):994-8. doi: 10.1038/leu.2014.329. Epub 2014 Nov 26. Leukemia. 2015. PMID: 25425197 No abstract available.
• Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets.
  López-Oreja I, Playa-Albinyana H, Arenas F, López-Guerra M, Colomer D. López-Oreja I, et al. Cancers (Basel). 2021 Jun 24;13(13):3150. doi: 10.3390/cancers13133150. Cancers (Basel). 2021. PMID: 34202439 Free PMC article. Review.
• NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.
  Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, Martorelli D, Bravin V, D'Agaro T, Rossi FM, Bomben R, Santinelli E, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Poeta G, Rossi D, Gaidano G, Dal Bo M, Gattei V, Zucchetto A. Benedetti D, et al. Leukemia. 2018 Mar;32(3):654-662. doi: 10.1038/leu.2017.296. Epub 2017 Sep 22. Leukemia. 2018. PMID: 28935990

References

1. 1. Annu Rev Immunol. 2010;28:343-65 - PubMed
2. 1. Science. 2004 Oct 8;306(5694):269-71 - PubMed
3. 1. Blood. 2009 Jan 22;113(4):856-65 - PubMed
4. 1. PLoS One. 2013;8(2):e57793 - PubMed
5. 1. Blood. 2012 Jan 12;119(2):329-31 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group
  • Ovid Technologies, Inc.

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information